IMPORTANT SAFETY INFORMATION:
Granisol™ (granisetron HCl) is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and with radiation, including total body irradiation and fractionated abdominal radiation. The most frequently reported clinical adverse events occurring in >5% of patients receiving Granisol™ were headache, constipation, asthenia, and diarrhea. The use of Granisol™ in patients following abdominal surgery or in patients with chemotherapy induced nausea and vomiting may mask progressive ileus and/or gastric distention. For full prescribing information, please click here.

If you do not have Adobe® Acrobat® Reader for viewing the pdfs shown above, you may download it free of charge by clicking here.